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Abstract
Background: While programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) checkpoint inhibitors
have activity in a proportion of patients with advanced bladder cancer, strongly predictive and prognostic
biomarkers are still lacking. In this study, we evaluated PD-L1 protein expression on circulating tumor cells (CTCs)
isolated from patients with muscle invasive (MIBC) and metastatic (mBCa) bladder cancer and explore the
prognostic value of CTC PD-L1 expression on clinical outcomes.
Methods: Blood samples from 25 patients with MIBC or mBCa were collected at UCSF and shipped to Epic
Sciences. All nucleated cells were subjected to immunofluorescent (IF) staining and CTC identification by
fluorescent scanners using algorithmic analysis. Cytokeratin expressing (CK)+ and (CK)−CTCs (CD45−, intact nuclei,
morphologically distinct from WBCs) were enumerated. A subset of patient samples underwent genetic
characterization by fluorescence in situ hybridization (FISH) and copy number variation (CNV) analysis.
Results: CTCs were detected in 20/25 (80 %) patients, inclusive of CK+ CTCs (13/25, 52 %), CK−CTCs (14/25, 56 %),
CK+ CTC Clusters (6/25, 24 %), and apoptotic CTCs (13/25, 52 %). Seven of 25 (28 %) patients had PD-L1+ CTCs; 4 of
these patients had exclusively CK−/CD45−/PD-L1+ CTCs. A subset of CTCs were secondarily confirmed as bladder
cancer via FISH and CNV analysis, which revealed marked genomic instability. Although this study was not powered
to evaluate survival, exploratory analyses demonstrated that patients with high PD-L1+/CD45−CTC burden and low
burden of apoptotic CTCs had worse overall survival.
Conclusions: CTCs are detectable in both MIBC and mBCa patients. PD-L1 expression is demonstrated in both CK+
and CK−CTCs in patients with mBCa, and genomic analysis of these cells supports their tumor origin. Here we
demonstrate the ability to identify CTCs in patients with advanced bladder cancer through a minimally invasive
process. This may have the potential to guide checkpoint inhibitor immune therapies that have been established to
have activity, often with durable responses, in a proportion of these patients.
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Background
Bladder cancer is the 5th most common cancer affecting
both men and women in the United States, with a rising
incidence worldwide [1, 2] (http://seer.cancer.gov/statfacts/
html/urinb.html). The prognosis for patients with muscle
invasive (MIBC) and metastatic (mBCa) bladder can-
cer is poor, with median survival with cisplatin-based
chemotherapy averaging 14 months in the metastatic set-
ting [3–6]. Urothelial bladder cancers have been found to
express the markers programmed death-1 (PD-1) and pro-
grammed death ligand 1 (PD-L1) [7]. Expression of PD-1
and PD-L1 on cancer cells is hypothesized to allow can-
cers to evade immune surveillance and eradication. The
discovery of this mechanism of resistance has provided
the rationale for the development of PD-1 and PD-L1
checkpoint immunotherapy.
PD-1 checkpoint immunotherapy is rapidly emerging
as a promising option for pre-treated patients with ad-
vanced tumors [8–11]. Multiple monoclonal antibodies
have been developed against PD-1, and its ligand, PD-
L1, and are currently being evaluated in clinical trials ei-
ther as monotherapy, or in combination with cytotoxic
chemotherapy, anti-angiogenic agents, or other immune
checkpoint inhibitors [12–14]. Complete responses have
been seen in heavily pre-treated patients, with some
patients garnering continued tumor regression off
therapy [15]. Early phase clinical trials have yielded
promising results across many tumor types, measured
both by response rate and duration of tumor response
[12, 13, 16–18]. As of 2016, immunotherapies target-
ing PD-1 or PD-L1 have been approved by the FDA
for the treatment of relapsed/refractory melanoma
[19], squamous cell lung cancer [20, 21], non-small
cell lung cancer [22], renal cell carcinoma [23], and
most recently bladder cancer [24].
While PD-1/PD-L1 blockade has activity across a num-
ber of cancers, in most studies, less than 50 % of patients
respond to treatment, indicating a need for predictive bio-
markers. While higher PD-1 or PD-L1 expression on
tumor biopsy specimens or tumor-infiltrating lymphocytes
has been correlated with an increased likelihood of re-
sponse [7], the positive and negative predictive value of
these assays remains modest [13, 14, 25]. In many clinical
studies PD-1 and PD-L1 expression has been assessed
on archived specimens and may not reflect the
current state of the cancer.
Obtaining solid tumor tissue biopsy specimens in-
volves an invasive, technically challenging procedure
posing risks to the patient. Instead, circulating tumor
cell (CTC) isolation and analysis from peripheral blood
samples may provide a fairly non-invasive approach to
identify biomarkers and serially monitor response to
treatment. Here, we present an assay for PD-L1 protein
expression on peripherally collected CTCs [26, 27] and
evaluate the incidence of circulating PD-L1+ CTCs in
blood samples from patients with bladder cancer.
Methods
Cell culture and preparation of cell line control slides
Authenticated cell line cells H820 (lung cancer),
Colo205 (colon cancer), A549 (lung cancer), SU-DHL-1
(lymphoma), H441 (lung cancer) and H23 (lung cancer),
were purchased from ATCC and cultured in RPMI 1640
media supplemented with 10 % fetal bovine serum. Where
applicable, cells were treated for 24 h with 100 ng/mL
IFN-γ (R&D Systems, Minneapolis, MN). Cell line cells
were then detached and spiked into healthy donor (HD)
blood, which was then processed per Epic Sciences stand-
ard operating procedure [28, 29]. Briefly, red blood cells
were lysed using ammonium chloride solution and the
remaining nucleated cells were plated onto glass slides at
a density of 3 million cells per slide. Slides were then
stored in a − 80 °C biorepository until used for immuno-
fluorescence (IF) staining and analysis.
Patient blood sample processing
Blood samples were collected from 25 bladder cancer
patients who consented to an IRB-approved protocol at
UCSF. Ten mL of whole blood was collected from each
patient in Cell Free DNA BCT tubes (Streck, Omaha, NE)
and shipped to Epic Sciences at ambient temperature for
processing. Red blood cells were lysed using ammonium
chloride solution, and nucleated cells were purified for dir-
ect deposition onto glass slides (at a density of 3 million
cells per slide) and subsequent storage in the − 80 °C
biorepository.
PD-L1 IF staining and analysis
Slides created from cell line control (CLC)-spiked HD
samples or bladder cancer patient samples were sub-
jected to automated IF staining for cytokeratin (CK),
CD45 (hematopoietic marker) and PD-L1 (clone E1L3N,
Cell Signaling Technology). Stained slides were analyzed
with fluorescent scanners and morphology algorithms
for the identification of traditional CK+ CTCs, CTC
clusters, apoptotic CTCs and CK−CTCs morphologically
distinct from hematological cells [26]. Trained classifiers
conducted final classification of CTC subpopulations
based on morphological parameters and biomarker ex-
pression. CLC slides were stained in parallel with patient
samples. Threshold for PD-L1 cell positivity in patient
samples was set to 95 % specificity of negative control
CLC signal (i.e., 95 % negative control cell line cells lie
below threshold).
Patient sample testing
CTC detection and classification on the Epic Sciences
platform has been described previously [28, 29]. In brief,
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slides created from bladder cancer patient samples
underwent automated IF staining for CK, CD45, and
PD-L1, and counterstained with DAPI to visualize nu-
clei. Up to two slides were stained and evaluated per pa-
tient sample with fluorescent scanners and morphology
algorithms for the identification of CTCs, CTC clusters,
and apoptotic CTCs. A more thorough description of
CTC types identified on the Epic Sciences platform has
been published previously [26]. Briefly, all CTCs are
strictly CD45−and have intact nuclei, with the exception
of apoptotic CTCs, which are defined by their fragmen-
ted nuclei. CTCs are classified by the presence or ab-
sence of CK staining, and whether they are single CTCs
or a CTC cluster. CK−CTCs must also exhibit distinctive
nuclear morphology compared to neighboring white
blood cells (WBCs) consistent with malignant origin.
Apoptotic CTCs were defined as CK+/CD45−CTCs with
DAPI pattern of chromosomal condensation and/or nu-
clear fragmentation and blebbing. A more detailed de-
scription of characterization of apoptotic CTCs has been
published previously [26, 30]. California-licensed Clinical
Laboratory Cytologists conduct final quality control of
CTC subpopulation classification.
Fluorescence in situ hybridization
Slide coordinates of every CTC are recorded during the
Epic Sciences CTC enumeration process, from which
CTCs were relocated and analyzed by fluorescence in
situ hybridization (FISH) for specific genetic alterations.
One patient with CK−/PD-L1+ CTCs was selected and
tested for genetic alterations by FISH. Coverslips were
removed, IF staining attenuated, and cells were fixed and
dehydrated. After dehydration, a probe solution (Cymogen
Dx, Irvine, CA) selected for bladder cancer to assess poly-
ploidy and gross genomic alterations in identified CTCs
(targeting the CEP3, CEP7, CEP10, 5p15 DNA sequences
of interest) was applied to each slide. After hybridization,
slides were then washed to remove the unbound probe,
counterstained with DAPI, and mounted with an anti-fade
mounting medium. Adjacent patient WBCs were used as
internal negative controls for endogenous genetic status
for each cell analyzed.
Cell Isolation, amplification, and next-generation sequencing
Non-apoptotic individual CTCs were relocated on the
slide based on a mathematical algorithm that converts
the original CTC positions (x and y coordinates) com-
puted during the scanning procedure into a new set of x,
y references compatible with the Nikon TE2000 inverted
immunofluorescent microscope used for cell capture.
Single cells were captured using an Eppendorf Transfer-
Man NK4 micromanipulator. Cells were deposited into
PCR tubes using 1 μL of TE buffer and single cell whole
genome amplification (WGA) was performed using
SeqPlex Enhanced (Sigma) according to the manufac-
turer’s instructions with minor modifications. For patient
copy number variation (CNV) analysis, 9 CK−/PD-L1+
CTCs from one patient were sequenced. Post-WGA,
DNA concentrations were determined by UV/Vis. Next-
Generation Sequencing (NGS) libraries were constructed
using NEBNext Ultra DNA Library Prep Kit for Illumina
(NEB) from 100 ng of WGA DNA as per manufacturer
recommendation with minor modifications. After NGS
library preparation, library concentrations and size dis-
tributions were determined with NEBNext Library
Quant Kit for Illumina (NEB) and Fragment Analyzer
(Advanced Analytical). Equinanomolar concentrations
from each library were pooled and sequenced on an Illu-
mina NextSeq 500 using a High Output Paired-End 2 ×
150 format (PE 2 × 150).
Genome wide copy number variation analysis was
performed using Epic single cell CNV analysis
pipeline. Briefly, raw sequencing data (FASTQ) were
aligned to hg38 human reference genome from UCSC
(http://hgdownload.soe.ucsc.edu/goldenPath/hg38/big-
Zips/) using Burrows-Wheeler Aligner (BWA, http://
bio-bwa.sourceforge.net). Binary alignment map files
(BAM) were filtered for quality (MAPQ 30) to keep
only the reads that have one or just a few “good” hits
to the reference sequence. Hg38 human genome was
divided into ~3000 bins of 1 million base pair and
reads were counted within each bin for each sample.
For each sample, read counts per bin were normal-
ized against white blood cell controls, and the ratios
were log2 transformed before plotted against genome
positions.
Clinical data collection and survival analysis
All patients consented to participate in this IRB-
approved research study prior to providing peripheral
blood samples for analysis. All patient identifiers were
removed prior to analysis by Epic Sciences. Clinical data
extracted from their charts were maintained and tracked
on a secure database. Overall survival was defined as the
length of time from the date of the blood draw till death
or last follow-up, and was calculated for patients who
maintained follow-up at UCSF. Survival analysis was
performed using the log-rank test and time-to-event
curves were plotted using the Kaplan-Meier method.
Results
Assessment of PD-L1 antibody specificity
To evaluate the specificity of the PD-L1 CTC assay,
anti-PD-L1 antibody and species-matched isotype con-
trols were tested on high PD-L1 expressing and negative
control cell lines (H820 and Colo205, respectively;
Fig. 1a). Membrane-localized staining was observed in
H820 cells stained with anti-PD-L1, whereas no staining
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was observed in negative control cell lines or with iso-
type control antibody. To further evaluate the specificity
of the assay for PD-L1 protein, Colo205, A549, and SU-
DHL-1 cell lines were treated with interferon gamma
(IFN-γ), a known cytokine that induces PD-L1 expres-
sion [31] (Fig. 1b). Negative (Colo205) or low (A549,
SU-DHL-1) PD-L1-expressing cell lines were selected
specifically to observe if IFN-γ was sufficient to up-
regulate PD-L1 protein expression. As detected by the
PD-L1 CTC assay, IFN-γ treatment increased PD-L1 ex-
pression in both Colo205 and A549 cells compared to un-
treated cells, however, PD-L1 expression in SU-DHL-1
cells remained unchanged. This observed insensitivity to
IFN-γ by SU-DHL-1 could be due to suppression of cyto-
kine signaling 3 (SOCS3) protein, known to be highly
expressed in SU-DHL-1, which inhibits the cytokine sig-
naling required for IFN-γ mediated PD-L1 induction [32].
PD-L1 assay development
Anti-PD-L1 titration curves were generated with cell line
controls expressing high (H820), medium (H441), low
(SU-DHL-1) and negative (H23, Colo205) levels of PD-
L1 (Fig. 2a). At the optimal antibody condition (1:2000
dilution), relative mean IF PD-L1 signal in H820, H441,
SU-DHL-1 was detected at 140-, 36-and 13-fold, re-
spectively, over baseline levels in negative control
Colo205 (Fig. 1c). As expected, PD-L1 staining in posi-
tive cell lines was observed to be enriched in the plasma
membrane (Fig. 1d) [33].
Patient characteristics
Demographics
Blood was obtained from 25 patients with bladder cancer
from May 2014 to January 2016. Follow-up data for clin-
ical outcomes was available for 19 patients. This cohort of
patients represented a broad range of burden of disease.
Overall, 17 men and 8 women participated in the study.
The median age of all participants was 67 (range: 43 –
89), 4 patients had MIBC at the time of draw and 21 had
mBCa. Fifteen of these patients had received prior che-
motherapy, with at least 12 receiving one or more
cisplatin-based regimens. Median time to blood draw
from diagnosis was 1075 days. Please refer to Table 2 for
median time to blood draw from diagnosis and prior ther-
apies received. Of note, two patients who contributed
samples had prior malignancies. One patient (B-026) had
a history of BRCA2 positive breast cancer with no evi-
dence of disease since 1993. The second patient (B-011)
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Fig. 1 PD-L1 CTC Assay Development (a) PD-L1-specific antibody and species-matched isotype control were tested in negative (Colo205) and
high (H820) PD-L1-expressing cell lines. Individual cellular PD-L1 IF signal is quantified and plotted. No staining above background was seen with
isotype control or in Colo205 stained with anti-PD-L1. b IFN-γ treatment increases PD-L1 expression in Colo205 and A549, while SU-DHL-1 is
insensitive. c PD-L1 antibody was titrated in PD-L1 IF staining of high (H820), medium (H441), low (SU-DHL-1) and negative (Colo205, H23) PD-L1-
expressing cell lines to determine assay sensitivity and dynamic range. At the optimal antibody concentration (1:2000 dilution), mean H820,
H441 and SU-DHL-1 PD-L1 expression was determined to be 140-, 36- and 13-fold higher than mean background staining in negative controls.
d Representative images of high, medium and negative PD-L1 expressing cell lines show membrane-localization of PD-L1 IF signal
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developed acute myeloid leukemia (AML) months after
his CTCs were drawn. This patient is included in the ana-
lysis as the CTCs were CD45−, while cells from AML were
found to be uniformly CD45+; FISH analysis performed
on these CD45− CTCs confirmed genomic alterations
consistent with bladder cancer, further discussed below.
See Table 1 for summary of patient demographics.
CTC Detection
CK+ single CTCs were detected in 13/25 (52 %) patient
samples. CK+ CTC Clusters were detected in 6/25 (24 %),
apoptotic CTCs were detected in 13/25 (52 %), and CK−
CTCs were detected in 14/25 (56 %) patient samples.
Combined, 20/25 (80 %) patient samples had detectable
CTCs of all subtypes. Interestingly, 3 of 4 patients with
MIBC had detectable CTCs (one patient had CK−CTCs,
one with CK+ CTCs, and one with apoptotic CTCs).
PD-L1 Expression on CTCs
Of the 20 patients with detectable CTCs, 7/20 (35 %) had
CTCs with PD-L1 positivity. Of these, five patients had
CK−/PDL1+ CTCs, with four of these patients having PD-
L1 positivity exclusively on CK− CTCs. Patients with PD-
L1 expression detectable on CTCs all had metastatic blad-
der cancer. See patient sample CTC summary in Table 2
and Fig. 2a. Thus far, seven patients have received PD-1
targeting therapy-one received it prior to CTC collection,
the remaining started therapy after blood collection.
CK− PDL1+ CD45−CTCs have gross genomic aberrations
To further assess the specificity of the PD-L1 assay in
patient samples, we analyzed CK−/CD45−/PD-L1+ CTCs
from two metastatic bladder cancer patients for genomic
abnormalities. Patient selection was determined by the
ability to perform FISH analysis, which excluded those
requiring PDL1 amplification during processing of the
samples. Thirty-three CK−/CD45−/PD-L1+ CTCs de-
tected in one mBCa patient (B-011) were analyzed by
FISH for genetic alterations commonly associated with
bladder cancer. As shown in Fig. 2c, the presence of these
genetic abnormalities in identified CTCs is consistent with
malignant origin. See detailed results in Table 3.
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Fig. 2 PD-L1 positive CTCs observable in patients with bladder cancer (a) Of the 7 total patients with PD-L1+ CTCs, two had exclusively CK+/PD-L1+
CTCs, four patients had CTCs that were exclusively CK−/PD-L1+, and one had both CK−and CK+/PD-L1+ CTCs. Further breakdown of CK+/PD-L1+ and
CK−/PD-L1+ CTCs detected by tumor subtype and staging indicates that inclusion of CK− CTCs substantially increased sensitivity of PD-L1+ CTC
detection. b Representative images of CK+/PD-L1+ and CK−/PD-L1+ patient CTCs are shown. c Representative FISH images of CK−/PD-L1+ cells
demonstrate gross genomic instability and polyploidy using DNA probes for CEP3 (aqua), CEP7 (orange), CEP10 (green) and 5p15 (red). 29/33 (88 %)
CK−/PD-L1+ cells assessed from one individual patient with high CTC burden were observed to have at least one abnormality determined by FISH
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Nine CK−/CD45−/PD-L1+ CTCs detected in a different
patient with metastatic disease (B-022) were further
assessed for CNV using NGS. Read count analysis of
these CTCs are provided in Additional file 1: Figure S1.
Five of nine (56 %) CTCs demonstrated a significant
number of genomic aberrations in chromosomal copy
number changes, including chromosomes 1, 2, 6, 17, 18,
20, 21, X and Y (Fig. 3a–e). Figure 3f depicts the ploidy
analysis of genomic aberrations seen in the CTC
evaluated in Fig. 3b. As seen, this shows numerous am-
plifications and deletions within multiple arms and chro-
mosomes. Interestingly, chromosome 6 and Y appear to
be diploid, while the remainder of the chromosomes
demonstrate some level of ploidy abnormality. Evaluat-
ing these results against copy number data available
from The Cancer Genome Atlas (TCGA) cohort of 412
MIBC patients, we found some concordant losses in
chromosomes 1, 2, 6, 17, and 18. These genomic aberra-
tions provide supporting data that the cells identified
were of malignant origin.
High circulating PD-L1+ CD45−CTC burden and overall
survival
Follow-up survival data was available for 19 of 25
patients. High burden of PD-L1+ CTC is defined as >1
PD-L1+ CTC/mL (n = 4). Low burden of PD-L1+ CTC is
defined as greater than 0, but less than 1 PD-L1+ CTC/
mL (n = 3). PD-L1+ negative staining was defined as 0
PD-L1+ CTCs/mL (n = 12). Recent data presented by
Boffa, et al. at the American Society of Clinical Oncology
(ASCO 2016) meeting, which utilized the Epic PD-L1
assay to demonstrate higher burden of PD-L1+ CTCs is
a poor prognostic factor in lung cancer compared those
patients with the highest burden of PD-L1+ CTCs to
low/negative PD-L1+ CTCs. Our analysis used a similar
approach evaluating highest burden of PD-L1+ CTCs
(>1/mL, n = 4) to the rest of the cohort (n = 15). While
no statistically significant conclusions could be drawn
from this data, patients with higher circulating PD-L1+
CTC burden had a shorter median overall survival (194
vs. 303 days, log-rank p = 0.416) compared to those with
low circulating PD-L1+ CTC burden (Additional file 2:
Figure S2A).
Of the seven patients who received PD-1 checkpoint
immunotherapy, follow-up survival data was available for
5 patients. One patient passed away after one cycle of
therapy. The remaining four patients received at least
three cycles of therapy. Two of four patients had detect-
able CTCs (B-025 and B-028). Only patient B-025 exhib-
ited PD-L1+ (1.3 %) CTCs. The patient demonstrated
progression on PD-1 immunotherapy on radiographic as-
sessment after cycle 5 of therapy and was discontinued.
The other three patients who lacked PD-L1+ CTCs also
demonstrated radiographic progression on PD-1 immuno-
therapy after 3, 6, and 8 cycles of therapy, respectively.
Apoptotic CTCs and overall survival
Thirteen out of 25 patients (52 %) were detected to have
apoptotic CTCs. Two of four patients with MIBC had
detectable apoptotic CTCs (B-003 = 1.8, B-015 = 1.5) and
11/16 (69 %) mBCa patients with detectable CTCs had
apoptotic CTCs. Kaplan-Meier analysis of all 13 patients
with apoptotic CTCs suggests a trend towards improved
overall survival in patients with apoptotic CTCs (Hazard
ratio = 0.4, 0.12–1.31; p = 0.159). See Additional file 2:
Figure S2B.
Discussion
In this study, we demonstrate the ability to detect PD-L1
positivity both in cell lines spiked into human blood as
well as in bladder cancer CTCs processed on the Epic
Sciences platform. Pre-clinically, using cell lines with
known PD-L1 expression, we observed assay specificity
for PD-L1 expression by IF staining. Furthermore, ex-
pression was found to be 140-fold higher in H820 (high
expressing) cells as compared to negative controls, indi-
cative of high dynamic range and assay sensitivity. This
is further supported by detection of upregulated PD-L1
expression on Colo205 and A549 cell lines treated with
IFN-γ.
We evaluated the clinical utility and feasibility of the
Epic Sciences PD-L1 CTC assay using 25 bladder cancer
Table 1 Baseline patient demographics
Number of patients 25
Age, y
Median 67
Min-max 43–89
Sex, n (%)
Male 17 (68.0)
Female 8 (32.0)
Extent of disease, n (%)
MIBC 4 (16.0)
mBCa 21 (84.0)
Prior chemotherapy, n (%) 15 (60.0)
Follow-up status, n (%)
Deceased 11 (44.0)
Alive 8 (32.0)
No follow-up 6 (24.0)
Median days to blood draw 1075
Survival after CTC draw, days
Median 167
Min-max 40–599
Abbreviations: Y, years, Min, minimum, Max, maximum, n, number of patients
per category
Anantharaman et al. BMC Cancer  (2016) 16:744 Page 6 of 11
patient samples of various stages (MIBC and mBCa).
While CTCs were detected in 3 of the 4 patients with
MIBC, PD-L1 expression was not identified in this small
sub-cohort of patients. PD-L1+ CTCs were detected in
7/20 (35 %) patients with mBCa, and four of these pa-
tients expressed PD-L1 exclusively on CK− CTCs. To
confirm that these cells were truly CTCs, CK−/PD-L1+
CTCs from one patient were evaluated using a bladder
cancer FISH probe panel and CK−/PD-L1+ CTCs from
another patient were assessed for CNV by NGS. Both of
these methods found genomic aberrations in CTCs con-
sistent with malignant origin. CNV analysis on 5 of 9
CTCs that underwent NGS showed marked chromo-
somal copy number variations with ploidy analysis of
one cell revealing a high level of aberrancy. Four of the
nine cells did not exhibit a large number of chro-
mosomal copy number variations (see Additional file 2:
Figure S2). The heterogeneity of aberrancies found in
these cells is consistent with prior findings of intratu-
moral DNA ploidy heterogeneity described in various
tumor types, including bladder cancer [34–36] and
highly supports malignant origin. The finding of patients
with exclusively CK−/PD-L1+ cells is intriguing as it
could suggest that cells undergoing mesenchymal differ-
entiation and metastasis may escape immune surveil-
lance potentially via expression of PD-L1. However, this
finding requires confirmation in a larger cohort. This
Table 2 CTCs detected in patient samples
CTC subtype/mL
Patient ID Extent of disease at
time of draw
Days from diagnosis
to draw
Cycles of chemo
prior to draw
CK+ CK+ Clusters CK- CK- Clusters Apoptotic PD-L1+ (%)a
B-002 MIBC 4882 2 0.0 0.0 1.1 0.0 0.0 0.0 (0.0)
B-003 MIBC 59 0 0.0 0.0 0.0 0.0 1.8 0.0 (0.0)
B-015 MIBC 58 0 1.0 0.0 0.0 0.0 1.5 0.0 (0.0)
B-018 MIBC 150 4b 0.0 0.0 0.0 0.0 0.0 0.0 (0.0)
B-001 mBCa 55 0 3.3 0.0 2.5 0.0 0.0 0.0 (0.0)
B-004 mBCa 553 4b 0.0 0.0 5.0 0.0 0.0 0.0 (0.0)
B-005 mBCa 225 4b 34.7 0.3 0.7 0.0 12.5 0.3 (0.9)
B-006 mBCa 27 0 7.6 1.5 1.5 0.0 0.0 0.0 (0.0)
B-007 mBCa 162 0 0.0 0.0 0.8 0.0 1.7 0.0 (0.0)
B-010 mBCa 1513 9 1.5 0.0 3.7 0.0 0.0 0.7 (14.3)
B-011 mBCa 633 0 153.2 6.4 2002.1 38.3 0.0 972.3 (44.2)
B-012 mBCa 4606 1 5.5 0.0 5.2 0.0 6.7 0.6 (5.7)
B-013 mBCa 423 5b 0.0 0.0 0.0 0.0 0.0 0.0 (0.0)
B-014 mBCa 43 2b 0.0 0.0 3.3 0.0 1.6 0.0 (0.0)
B-016 mBCa 939 4b 11.9 0.6 5.8 1.0 1.0 0.0 (0.0)
B-017 mBCa 109 0 0.0 0.0 0.0 0.0 0.8 0.0 (0.0)
B-019 mBCa 163 4b 0.0 0.6 1.3 0.0 0.0 1.3 (66.7)
B-020 mBCa 815 8b 4.2 0.0 0.0 0.8 1.7 0.0 (0.0)
B-022 mBCa 7119 20b 4.3 0.0 22.9 0.0 5.7 12.9 (47.4)
B-023 mBCa 444 5 0.0 0.0 0.0 0.0 0.0 0.0 (0.0)
B-025 mBCa 1659 0 76.6 4.3 2.1 0.0 1.1 1.1 (1.3)
B-026 mBCa 724 5b 4.2 0.0 0.0 0.0 2.1 0.0 (0.0)
B-027 mBCa 271 4b 0 0 0 0 0 0.0 (0.0)
B-028 mBCa 247 0 0.9 0 0 0 1.8 0.0 (0.0)
B-029 mBCa 996 0 0 0 0 0 0 0.0 (0.0)
a Includes CK+ and CK−CTCs
b indicates patient received at least one cisplatin regimen
Table 3 Assessment of CK-/PD-L1+ CTCs for genetic alterations
by FISH
FISH status Pt 11 CK-CTCs (N = 33)
No abnormalities, n (%) 4 (12.1)
At least 1 abnormality, n (%) 29 (87.9)
All abnormalities, n (%) 17 (51.5)
Abbreviations: N, number of CTC analyzed for genetic alterations by FISH, n,
number of CTCs per category
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also points to the utility of using a CTC enrichment
technique that does not require CK expression.
It has previously been demonstrated in bladder cancer
and other solid tumors using tissue biopsy staining that
patients fare worse if their tumors are able to evade the
immune system [37]. While these patient samples repre-
sent a small, cross-sectional cohort rather than a pro-
spective controlled trial, it is worth noting that those
with the highest PD-L1+ CTC burden (>1/mL) had a
shorter overall survival from the time of the CTC draw.
Furthermore, evaluation of apoptotic CTC counts dem-
onstrated a trend toward shorter survival for those with
fewer apoptotic CTCs. Fewer apoptotic cells have been
observed in patients with metastatic breast cancer com-
pared to those with early stage disease, suggesting a cor-
relation between lack of apoptosis with cell survival and
an aggressive phenotype [38]. Of note, the time of CTC
draw was highly variable across our patient population
and represented snapshots of a wide range of burden of
disease and prior therapies. Some patients were actively
undergoing chemotherapy at the time of their draw,
which could influence the burden of total and apoptotic
CTCs detected. The aim of this study was to demon-
strate feasibility and consistency in detecting PD-L1
+CTCs in bladder cancer and was not powered to evaluate
survival benefits. Further evaluation and optimization in a
larger and more uniform cohort with appropriate power
and design is warranted to better evaluate the association
of PD-L1 expression and apoptotic CTCs with survival.
Biomarkers to predict response to PD-1-directed ther-
apies are far from established. Higher PD-L1 expression
in solid tumor biopsy samples is associated with re-
sponse to pembrolizumab in non-small cell lung cancer
[20] and correlates with response to therapy in other in-
dications [14, 39, 40]. However, a significant portion of
PD-L1− patients also respond to therapy. Recent multi-
focal genetic and proteomic analyses of regions within
tumors have revealed levels of spatial heterogeneity in
several cancer types that might limit the interpretation
of solid tumor biopsies [41–45]. Due to tumor hetero-
geneity, smaller sample size or intratumoral location of
the biopsy site may yield a false negative tissue assess-
ment of PD-L1. Similarly, PD-L1 expression is thought
to be dynamic and can vary in response to interferon
levels and possibly other factors, making the reliability of
a static assessment on a limited tumor tissue sample
questionable. While it would be challenging to monitor
expression via serial tumor tissue biopsies, it is much
more feasible to monitor expression of this dynamic
marker via serial CTC assessment from whole blood. It
may even be possible to detect PD-L1+ CTCs in patients
who are PD-L1−on tissue biopsy. The correlation of
CTC PD-L1 status with paired tumor tissue samples and
the implications of discordant expression was not
Fig. 3 Genomic heterogeneity of bladder cancer CTCs. Plots of whole genome CNV profiles of five CK−/CD45−/PD-L1+ CTCs from patient B-022
(a-e). X axis: chromosomes displayed as from chromosome 1 to 22, X and Y (from left to right, shifted by red and blue color); Y axis: normalized
log2 transformed ratio of copy number of test sample over that of WBC control. Five CTCs show various genomic aberrations a loss of chromosome 1,
2, 17, 18, and 20; b loss of chromosome 6; c gain of chromosome 21; d and e gain of chromosome X and loss of chromosome Y. f Ploidy analysis for
genomic aberrations from NSG seen in CTC (b), predicted ploidy = 3.25
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pursued in this study, but will be important for future
assessment. Similarly, five evaluable patients received
PD-1 targeting therapy after blood was drawn for ana-
lysis of CTCs. One patient had a rapid decline after ther-
apy and the remaining 4 patients demonstrated
radiographic progression after 3, 6, and 8 cycles of PD-1
checkpoint immune therapy. Serial blood draws were
not performed in this study. Therefore there was an in-
sufficient sample size to assess the prognostic value of
PD-L1+ CTCs in patients receiving checkpoint inhibi-
tors. This would be best explored in a prospective study
with a larger cohort of patients with similar disease bur-
den receiving PD-1 or PD-L1 checkpoint therapy.
Another limiting factor in the analysis of PD-L1 ex-
pression in solid tumor samples is the lack of
standardization of PD-L1 immunohistochemical assays
and their respective positivity thresholds [13, 14]. CTCs
provide a minimally-invasive sampling method that
could prove useful for prognostication of therapeutic
benefit through longitudinal monitoring and measure-
ment of pharmacodynamic changes in CTC counts and/
or changes of CTC PD-L1 expression. The Epic Sciences
CTC platform utilizes a central laboratory for consistent
quality with a central biorepository for retrospective ana-
lyses of biomarkers on morphologically intact CTCs.
Analytical validation studies of Epic’s CTC platform have
been published [26]. In addition, this platform has previ-
ously been compared to the FDA approved CellSearch
platform (Janssen Diagnostics, NJ, USA) demonstrating
consistent, if not increased sensitivity in the detection of
CTCs [27]. Using this technology, repeat sampling of pa-
tients utilizing CTCs is both feasible and amenable to
pharmacodynamic biomarker development to identify
not only patients that might respond, but those who are
responding to therapy.
Conclusions
Our findings demonstrate the ability to detect and quan-
tify PD-L1 protein on bladder cancer patients’ CTCs
using an assay with specificity and sensitivity demon-
strated in CTC surrogate cell lines. Exploratory analysis
of survival data suggests a trend towards improved sur-
vival in those with low PD-L1 expression or with higher
burden of apoptotic CTCs. While the data presented
here are compelling, it should be emphasized that this
study is descriptive, represents a small sample size, and
requires validation with a larger, prospective study
encompassing a broader patient population that is ap-
propriately powered to evaluate survival benefits. None-
theless, these data provide initial support for broader
development of CTC PD-L1 expression. With further
study, PD-L1 expression on CTCs isolated from periph-
eral circulation has the potential to become a new prog-
nostic and predictive biomarker with which to stratify
treatments for patients and possibly predict response to
immunotherapy in bladder cancer.
Additional files
Additional file 1: Sequencing read counts for 10 CTCs from two
patients with metastatic bladder cancer undergoing NGS. (PPTX 48 kb)
Additional file 2: (A) Kaplan-Meier curve of OS for patients with high
(solid line) and low (dotted line) PD-L1+ CTC burden (high burden ≥ 1
PD-L1+ CTC/mL). (B) Kaplan-Meier curve of OS for patients with apoptotic
CTCs (dotted line) and without apoptotic CTCs (solid line). (PPTX 71 kb)
Abbreviations
BAM: Binary Alignment Map; CK: Cytokeratin; CLC: Cell line control;
CNV: Copy number variation; CTC: Circulating tumor cell; FISH: Fluorescence
in situ hybridization; HD: Healthy donor; IF: Immunofluorescence; IFN-γ: Interferon
gamma; mBCa: Metastatic bladder cancer; MIBC: Muscle-invasive bladder
cancer; NGS: Next generation sequencing; PD-1: Programmed death 1;
PD-L1: Programmed death ligand 1; TCGA: The cancer genome atlas;
WBC: White blood cell; WGA: Whole genome amplification
Acknowledgements
We would like to thank Andrew Phillips and Bernard Schwartz for funding
support, and Stephanie Greene, Angel Rodriguez, Jerry Lee, Mark Landers,
and for their assistance with the CTC sequencing.
Funding
The UCSF philanthropic fund was the primary source of funding for this study.
Availability of data and materials
The data collected is not publically available, but could be made so upon
request.
Authors’ contributions
AA, TWF, DL, RK, GP, JH, ME, RP, KL,RG, AJ, JL, LD, SB, YW, RD, and PP
contributed to data collection. DL, RK, GP, KL, RG, AJ, and JL contributed to
assay development, processing collected specimens, and all analyses related
to CTC characterization, staining, and statistics. DL, RK, RG, AJ, JW, LD, YP, and
RD contributed to PD1 assay development. GP and KL contributed to
analysis of genetic studies. JH, ME, and RP were responsible for the database
lock, patient sample collection, and data gathering. AA, TWF, and PP
contributed to data analysis, data interpretation, and writing of the
manuscript. YP, SB, and RD contributed to editing the report and oversight
of author review of the report. AA, TF, RG, SB, YP, and RD contributed to the
design of the figures. AA, TWF, YW, RD, PP, and the other authors were
involved in data analysis and interpretation; the drafting, review, and
approval of the report; and the decision to submit for publication. All read
and approved the final manuscript.
Competing interests
DL, RK, RG, AJ, JL, LD, SB, YW and RB are employees of Epic Sciences.
Consent for publication
This manuscript does not contain any individual person data.
Ethics approval and consent to participate
This is a study approved by the UCSF Committee on Human Research. All
patients who contributed samples signed a consent to participate in this
study after going through a consenting packet with a physician, who
expressed their right to refuse participation.
Author details
1Division of Hematology-Oncology, Helen Diller Family Comprehensive
Cancer Center, University of California at San Francisco, 1825 4th Street, 6th
Floor, San Francisco, CA 94158, USA. 2Epic Sciences, San Diego, CA, USA.
3Department of Urology, Helen Diller Family Comprehensive Cancer Center,
University of California at San Francisco, San Francisco, CA, USA.
Anantharaman et al. BMC Cancer  (2016) 16:744 Page 9 of 11
Received: 3 June 2016 Accepted: 31 August 2016
References
1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary
bladder cancer in the world. World J Urol. 2009;27(3):289–93.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin.
2014;64(1):9–29.
3. Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M,
Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E,
Raghavan D, Marreaud S, Collette S, Sylvester R, De Wit R. Randomized
phase III study comparing paclitaxel/cisplatin/gemcitabine and
gemcitabine/cisplatin in patients with locally advanced or metastatic
urothelial cancer without prior systemic therapy: EORTC Intergroup Study
30987. J Clin Oncol. 2012;30(10):1107–13.
4. Sternberg CN, De Mulder P, Schornagel JH, Theodore C, Fossa SD, Van
Oosterom AT, Witjes JA, Spina M, Van Groeningen CJ, Duclos B, Roberts JT,
De Balincourt C, Collette L, EORTC Genito-Urinary Cancer Group. Seven year
update of an EORTC phase III trial of high-dose intensity M-VAC
chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract
tumours. Eur J Cancer. 2006;42(1):50–4.
5. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ,
Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall
P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF.
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin,
and cisplatin in advanced or metastatic bladder cancer: results of a large,
randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;
18(17):3068–77.
6. International Collaboration of Trialists, Medical Research Council Advanced
Bladder Cancer Working Party (now the National Cancer Research Institute
Bladder Cancer Clinical Studies Group), European Organisation for Research
and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian
Bladder Cancer Study Group, National Cancer Institute of Canada Clinical
Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, Club
Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R,
Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing
neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for
muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
J Clin Oncol. 2011;29(16):2171–7.
7. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris
HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang
NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic
bladder cancer. Nature. 2014;515(7528):558–62.
8. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune
responses: the unique properties of PD-1 and their advantages for clinical
application. Nat Immunol. 2013;14(12):1212–8.
9. Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A.
Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol.
2014;153(1):145–52.
10. Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I.
Orchestrating immune check-point blockade for cancer immunotherapy in
combinations. Curr Opin Immunol. 2014;27:89–97.
11. Razzak M. From ASCO-targeted therapies: Anti-PD-1 approaches–important
steps forward in metastatic melanoma. Nat Rev Clin Oncol. 2013;10(7):365.
12. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy:
review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;
11(1):24–37.
13. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer
Immunotherapy. Mol Cancer Ther. 2015;14(4):847–56.
14. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1
antibodies. Int Immunol. 2015;27(1):39–46.
15. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H,
Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable cancer
regression off-treatment and effective reinduction therapy with an anti-PD-1
antibody. Clin Cancer Res. 2013;19(2):462–8.
16. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C,
Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A,
Miller Jr WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT,
Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously
untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.
17. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM,
Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg
SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong
Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab
in advanced melanoma. N Engl J Med. 2013;369(2):122–33.
18. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF,
Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR,
Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA,
Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S,
McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity,
and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;
366(26):2443–54.
19. Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus
on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers
Med. 2014;7:357–65.
20. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A,
Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann
MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J,
Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L,
KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell
lung cancer. N Engl J Med. 2015;372(21):2018–28.
21. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E,
Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor
J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M,
Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab
versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med. 2015;373(2):123–35.
22. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ,
Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA,
Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi
N, Crino L, Blumenschein Jr GR, Antonia SJ, Dorange C, Harbison CT, Graf
Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced
Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):
1627–39.
23. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S,
Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK,
Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y,
Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman
IM, Sharma P, CheckMate 025 Investigators. Nivolumab versus Everolimus in
Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–13.
24. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV,
Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, Srinivas S,
Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-
Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D,
Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD,
Dreicer R. Atezolizumab in patients with locally advanced and metastatic
urothelial carcinoma who have progressed following treatment with
platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Lancet. 2016;387(10031):1909–20.
25. Errico A. Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade
against cancer. Nat Rev Clin Oncol. 2015;12(2):63.
26. Werner SG RP, Landers M, Valenta DT, Schroeder M, Greene S, Bales N,
Dittamore R, Marrinucci D. Analytical Validation and Capabilities of the Epic
CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and
Characterization. J Circulating Biomarkers. 2015;4:3.
27. Punnoose EA, et al. PTEN loss in circulating tumour cells correlates with
PTEN loss in fresh tumour tissue from castration-resistant prostate cancer
patients. Br J Cancer. 2015.
28. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E,
Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K,
Kuhn P: Characterization of circulating tumor cell aggregates identified in
patients with epithelial tumors. Phys Biol 2012, 9(1):016001-3975/9/1/
016001. Epub 2012 Feb 3.
29. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F,
Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward
M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y,
Sok D, Nelson D, Kuhn P: Fluid biopsy in patients with metastatic prostate,
pancreatic and breast cancers. Phys Biol 2012, 9(1):016003-3975/9/1/016003.
Epub 2012 Feb 3.
30. Wickman G, Julian L, Olson MF. How apoptotic cells aid in the removal of
their own cold dead bodies. Cell Death Differ. 2012;19(5):735–42.
Anantharaman et al. BMC Cancer  (2016) 16:744 Page 10 of 11
31. Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK,
Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S. Tumor cell
programmed death ligand 1-mediated T cell suppression is overcome by
coexpression of CD80. J Immunol. 2011;186(12):6822–9.
32. Cho-Vega JH, Rassidakis GZ, Amin HM, Tsioli P, Spurgers K, Remache YK,
Vega F, Goy AH, Gilles F, Medeiros LJ. Suppressor of cytokine signaling 3
expression in anaplastic large cell lymphoma. Leukemia. 2004;18(11):1872–8.
33. Fay AP, Signoretti S, Callea M, Telomicron GH, McKay RR, Song J, Carvo I,
Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS,
Freeman GJ, Elfiky A, Choueiri TK. Programmed death ligand-1 expression in
adrenocortical carcinoma: an exploratory biomarker study. J Immunother
Cancer. 2015;3:3-015–0047-3. eCollection.
34. Sasaki K, Hamano K, Kinjo M, Hara S. Intratumoral heterogeneity in DNA
ploidy of bladder carcinomas. Oncology. 1992;49(3):219–22.
35. Furuya T, Uchiyama T, Murakami T, Adachi A, Kawauchi S, Oga A, Hirano T,
Sasaki K. Relationship between chromosomal instability and intratumoral
regional DNA ploidy heterogeneity in primary gastric cancers. Clin Cancer
Res. 2000;6(7):2815–20.
36. Schvimer M, Lash RH, Katzin WE. Intratumoral heterogeneity of DNA ploidy
in breast carcinomas: a flow cytometric assessment of sampling techniques.
Cytometry. 1995;22(4):292–6.
37. Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and Survival in Solid Tumors: A
Meta-Analysis. PLoS ONE. 2015;10(6), e0131403.
38. Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D,
Stournaras C, Georgoulias V, Agelaki S. Apoptotic circulating tumor cells in
early and metastatic breast cancer patients. Mol Cancer Ther. 2013;12(9):
1886–95.
39. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA,
McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP,
Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I,
Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.
40. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L,
Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork
C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA,
Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1
blockade induces responses by inhibiting adaptive immune resistance.
Nature. 2014;515(7528):568–71.
41. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E,
Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S,
McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani
M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M,
Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity
and branched evolution revealed by multiregion sequencing. N Engl J Med.
2012;366(10):883–92.
42. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity.
Nature. 2013;501(7467):328–37.
43. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow
CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C,
Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV,
Hong WK, Swisher S, Wistuba II, Futreal PA. Intratumor heterogeneity in
localized lung adenocarcinomas delineated by multiregion sequencing.
Science. 2014;346(6206):256–9.
44. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic.
Nature. 2013;501(7467):355–64.
45. Crockford A, Jamal-Hanjani M, Hicks J, Swanton C. Implications of
intratumour heterogeneity for treatment stratification. J Pathol.
2014;232(2):264–73.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Anantharaman et al. BMC Cancer  (2016) 16:744 Page 11 of 11
